ImageneBio, Inc. (IMA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

ImageneBio, Inc. (IMA) closed at USD 4.15 on 2026-10-14, a change of -52.3 % over the past year, with a market capitalization of USD 45.75M.

ImageneBio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

ImageneBio, Inc. key figures

Previous close

USD 4.15 (2026-10-14)

1-year change

-52.3 %

Market cap

USD 45.75M

Enterprise value

USD -88.49M

P/E ratio (trailing)

-1.02

P/E ratio (forward)

-0.94

EPS (trailing)

-3.97

EPS (forward)

-4.31

PEG ratio

n/a

Price to book

0.32

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.94

Employees

18

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About ImageneBio, Inc.

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for ImageneBio, Inc. and compare it with other stocks.